Definition
Mezlocillin is a β‑lactam antibiotic of the penicillin class that is employed in the treatment of a variety of bacterial infections. It is administered parenterally, most commonly by intravenous infusion.
Overview
Mezlocillin was developed in the 1970s as an extended‑spectrum penicillin. It exhibits activity against many Gram‑negative organisms, including Pseudomonas aeruginosa, as well as several Gram‑positive bacteria. The drug is often used in hospital settings for serious infections such as sepsis, lower respiratory tract infections, intra‑abdominal infections, and urinary tract infections when broader coverage is required. Its clinical use is limited in some countries due to the availability of newer β‑lactam/β‑lactamase inhibitor combinations. Mezlocillin is supplied as the sodium salt (mezlocillin sodium) for parenteral injection.
Etymology/Origin
The name “mezlocillin” follows the conventional nomenclature for penicillins, where the suffix “‑cillin” denotes a penicillin derivative. The prefix “mez‑” may derive from a chemical descriptor of its side‑chain structure, though the precise origin of the term has not been formally documented in publicly available pharmaceutical literature.
Characteristics
- Chemical structure: Mezlocillin is a semisynthetic penicillin possessing a thienyl‑acyl side chain attached to the 6‑aminopenicillanic acid nucleus, which confers enhanced activity against certain Gram‑negative organisms.
- Spectrum of activity: Effective against many aerobic Gram‑negative bacilli (e.g., Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa), some Gram‑positive cocci (e.g., Streptococcus spp.), and selected anaerobes. It is inactivated by many β‑lactamases; susceptibility testing is required for specific isolates.
- Pharmacokinetics: Following intravenous administration, mezlocillin distributes widely in body fluids and tissues. It is primarily eliminated unchanged by the kidneys; dosage adjustment is necessary in renal impairment.
- Adverse effects: As with other penicillins, common adverse reactions include hypersensitivity reactions (rash, urticaria, anaphylaxis), gastrointestinal disturbances (nausea, diarrhea), and possible alterations in normal flora leading to secondary infections (e.g., Clostridioides difficile colitis).
- Resistance considerations: The emergence of β‑lactamase‑producing organisms and efflux mechanisms can limit mezlocillin efficacy. Combination with β‑lactamase inhibitors or use of alternative agents may be preferred where resistance is prevalent.
Related Topics
- Penicillins – the broader class of β‑lactam antibiotics to which mezlocillin belongs.
- β‑Lactam antibiotics – a major group of antibacterial agents that share a common β‑lactam ring structure.
- Antibiotic resistance – mechanisms by which bacteria evade the activity of β‑lactam antibiotics, relevant to mezlocillin’s clinical utility.
- β‑Lactamase inhibitors – compounds such as tazobactam and clavulanic acid that can be paired with penicillins to overcome certain resistance mechanisms.
- Pharmacokinetics and dosing in renal impairment – important considerations for dosing mezlocillin in patients with reduced kidney function.